Patent application number | Description | Published |
20100317568 | Anti-Viral Compounds - Compounds effective in inhibiting replication of Hepatitis C virus (“HCV”) are described. This invention also relates to processes of making such compounds, compositions comprising such compounds, and methods of using such compounds to treat HCV infection. | 12-16-2010 |
20110092415 | Anti-Viral Compounds - Compounds effective in inhibiting replication of Hepatitis C virus (“HCV”) are described. This invention also relates to processes of making such compounds, compositions comprising such compounds, and methods of using such compounds to treat HCV infection. | 04-21-2011 |
20110207699 | Anti-Viral Compounds - Compounds effective in inhibiting replication of Hepatitis C virus (“HCV”) are described. This invention also relates to processes of making such compounds, compositions comprising such compounds, and methods of using such compounds to treat HCV infection. | 08-25-2011 |
20120004196 | Anti-Viral Compounds - Compounds effective in inhibiting replication of Hepatitis C virus (“HCV”) are described. This invention also relates to processes of making such compounds, compositions comprising such compounds, and methods of using such compounds to treat HCV infection. | 01-05-2012 |
20120122842 | NAMPT AND ROCK INHIBITORS - Disclosed are compounds which inhibit the activity of NAMPT, compositions containing the compounds and methods of treating diseases during which NAMPT is expressed. Disclosed are compounds which inhibit the activity of ROCK, compositions containing the compounds and methods of treating diseases during which ROCK is expressed. | 05-17-2012 |
20120220562 | Anti-Viral Compounds - Compounds effective in inhibiting replication of Hepatitis C virus (“HCV”) are described. This invention also relates to processes of making such compounds, compositions comprising such compounds, and methods of using such compounds to treat HCV infection. | 08-30-2012 |
20120245124 | TRPV3 Modulators - Disclosed herein are modulators of TRPV3 of formula (I) | 09-27-2012 |
20130085141 | SUBSTITUTED OCTAHYDROPYRROLO[1,2-a]PYRAZINE SULFONAMIDES AS CALCIUM CHANNEL BLOCKERS - The present application relates to: (a) compounds of Formula (I): | 04-04-2013 |
20130085142 | SUBSTITUTED OCTAHYDROPYRROLO[1,2-a]PYRAZINES AS CALCIUM CHANNEL BLOCKERS - The present application relates to: (a) compounds of Formula (I): | 04-04-2013 |
20130158067 | TRPV1 Antagonists - Disclosed herein are compounds of formula (I): | 06-20-2013 |
20130172334 | TRPV1 ANTAGONISTS - Disclosed herein are compounds of formula (I): | 07-04-2013 |
20130216497 | NOVEL TRICYCLIC COMPOUNDS - The invention provides compounds of Formula (I) and Formula (II) | 08-22-2013 |
20130345255 | TRPV1 ANTAGONISTS - Disclosed herein are compounds of formula (I) or pharmaceutically acceptable salts, prodrugs, or combinations thereof, | 12-26-2013 |
20140256705 | BROMODOMAIN INHIBITORS - The present invention provides for compounds of formula (I) | 09-11-2014 |
20140315792 | ANTI-VIRAL COMPOUNDS - Compounds effective in inhibiting replication of Hepatitis C virus (“HCV”) are described. This invention also relates to processes of making such compounds, compositions comprising such compounds, and methods of using such compounds to treat HCV infection. | 10-23-2014 |
20140349970 | NOVEL TRICYCLIC COMPOUNDS - The invention provides a compound of Formula (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), (Ih), (Ii), (Ij), (Ik), or (Il) as defined herein, pharmaceutically acceptable salts, pro-drugs, biologically active metabolites, stereoisomers and isomers thereof wherein the variable are defined herein. The compounds of the invention are useful for treating immunological and oncological conditions. | 11-27-2014 |
20150087618 | Anti-Viral Compounds - Compounds effective in inhibiting replication of Hepatitis C virus (“HCV”) are described. This invention also relates to processes of making such compounds, compositions comprising such compounds, and methods of using such compounds to treat HCV infection. | 03-26-2015 |